Immunome IMNM Proceeds From Public Offering
Proceeds From Public Offering at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept imnm:ProceedsFromPublicOffering.
The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunome's proceeds from public offering.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Immunome's proceeds from public offering?
- Immunome (IMNM) reported proceeds from public offering of $0 in Q1 2026.
- What does proceeds from public offering mean?
- This represents the gross cash inflows received from the issuance of equity or debt securities to the public markets. It serves as a primary indicator of a company's ability to access capital markets to fund operations, research, or expansion. High proceeds often signal strong investor confidence but may also indicate significant dilution for existing shareholders.